The following is a summary of “Paradoxical GH response at OGTT does not predict Pasireotide efficacy but matters for glucose metabolism,” published in the January 2025 issue of Endocrinology by Occhi ...

When Ray Kohn started feeling pain in his knees and elbows in 2015, he attributed it to his work as a stunt driver and mechanic. But as the years went on, he began to notice his body changing in ...

There has been a surge in the pace of wage growth but a rise in the jobless rate following a big drop in the number of payrolled employees, according to the latest official figures. The Office for ...

But as the years went on, he began to notice his body changing in unusual ways: His head grew so much that he needed a larger helmet, and his hands became so big he had to have his wedding ring ...

The economy “recovered remarkably” in the fourth quarter of 2024, said the National Bureau of Statistics, growing 5.4 per cent year on year and rebounding from slower growth in the third quarter.

The UK economy just about returned to growth in November after two months of contraction, the latest official figures show. Gross domestic product (GDP), the standard measure of an economy's value ...

has a numerically neat formula to describe the objectives he believes the new administration should target as it pursues an aggressively pro-growth economic strategy. Mr. Bessent is a fervent ...

At this point, it is important to know that this forward P/E ratio is based on roughly 14% EPS growth this year, which would make it one of the best years since the Great Financial Crisis.

Growth disorders are disorders that affect the patient's height, weight and sexual development. These disorders are typically the result of atypical levels of growth hormone and patients can have ...

A growth disorder is a health issue that prevents a child from growing and physically developing as expected. These include certain syndromes, genetic disorders, and hormone imbalances.

Second Lead Pipeline Program Announced: MAR002 for the Treatment of Acromegaly MAR002 is a potential first-in-class anti-growth hormone receptor (GHR) antibody being developed for acromegaly.

A majority (nearly 75%) of patients with acromegaly will have a pituitary macroadenoma (>10 mm) at the time of diagnosis, giving rise to the complications of mass effect: headache, visual loss, and ...